Edwards Lifesciences Corp
Edwards Lifesciences Corporation provides products and technologies to treat advanced cardiovascular diseases in the United States, Europe, Japan, and internationally. The company offers transcatheter heart valve replacement products for minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement prod… Read more
Market Cap & Net Worth: Edwards Lifesciences Corp (EW)
Edwards Lifesciences Corp (NYSE:EW) has a market capitalization of $48.49 Billion ($48.49 Billion) as of March 18, 2026. Listed on the NYSE stock exchange, this USA-based company holds position #484 globally and #389 in its home market, demonstrating a 2.35% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Edwards Lifesciences Corp's stock price $83.56 by its total outstanding shares 580300000 (580.30 Million).
Edwards Lifesciences Corp Market Cap History: 2015 to 2026
Edwards Lifesciences Corp's market capitalization history from 2015 to 2026. Data shows growth from $15.28 Billion to $48.49 Billion (12.19% CAGR).
Index Memberships
Edwards Lifesciences Corp is a constituent of 1 market index:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
S&P 500 Index
GSPC
|
$53.10 Trillion | 0.09% | #215 of 503 |
Weight: Edwards Lifesciences Corp's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Edwards Lifesciences Corp Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Edwards Lifesciences Corp's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
8.15x
Edwards Lifesciences Corp's market cap is 8.15 times its annual revenue
0.67x
Higher than industry averageLatest Price to Earnings (P/E) Ratio
46.08x
Edwards Lifesciences Corp's market cap is 46.08 times its annual earnings
1.97x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $18.12 Billion | $2.96 Billion | $569.50 Million | 6.12x | 31.83x |
| 2017 | $21.80 Billion | $3.44 Billion | $622.10 Million | 6.35x | 35.05x |
| 2018 | $29.63 Billion | $3.72 Billion | $722.20 Million | 7.96x | 41.02x |
| 2019 | $45.13 Billion | $4.35 Billion | $1.05 Billion | 10.38x | 43.10x |
| 2020 | $52.94 Billion | $4.39 Billion | $823.40 Million | 12.07x | 64.30x |
| 2021 | $75.18 Billion | $5.23 Billion | $1.50 Billion | 14.37x | 50.02x |
| 2022 | $43.30 Billion | $5.38 Billion | $1.52 Billion | 8.04x | 28.45x |
| 2023 | $44.25 Billion | $6.00 Billion | $1.40 Billion | 7.37x | 31.55x |
| 2024 | $42.96 Billion | $5.44 Billion | $4.17 Billion | 7.90x | 10.29x |
| 2025 | $49.47 Billion | $6.07 Billion | $1.07 Billion | 8.15x | 46.08x |
Competitor Companies of EW by Market Capitalization
Companies near Edwards Lifesciences Corp in the global market cap rankings as of March 18, 2026.
Key companies related to Edwards Lifesciences Corp by market ranking:
- Abbott Laboratories (NYSE:ABT): Ranked #79 globally with a market cap of $190.05 Billion USD.
- Stryker Corporation (NYSE:SYK): Ranked #153 globally with a market cap of $121.18 Billion USD.
- GE HealthCare Technologies Inc. (NASDAQ:GEHC): Ranked #649 globally with a market cap of $32.05 Billion USD.
- DexCom Inc (NASDAQ:DXCM): Ranked #786 globally with a market cap of $25.41 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #79 | Abbott Laboratories | NYSE:ABT | $190.05 Billion | $109.95 |
| #153 | Stryker Corporation | NYSE:SYK | $121.18 Billion | $349.56 |
| #649 | GE HealthCare Technologies Inc. | NASDAQ:GEHC | $32.05 Billion | $72.17 |
| #786 | DexCom Inc | NASDAQ:DXCM | $25.41 Billion | $66.34 |
Edwards Lifesciences Corp Historical Marketcap From 2015 to 2026
Between 2015 and today, Edwards Lifesciences Corp's market cap moved from $15.28 Billion to $ 48.49 Billion, with a yearly change of 12.19%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $48.49 Billion | -1.98% |
| 2025 | $49.47 Billion | +15.16% |
| 2024 | $42.96 Billion | -2.91% |
| 2023 | $44.25 Billion | +2.20% |
| 2022 | $43.30 Billion | -42.41% |
| 2021 | $75.18 Billion | +42.00% |
| 2020 | $52.94 Billion | +17.32% |
| 2019 | $45.13 Billion | +52.31% |
| 2018 | $29.63 Billion | +35.90% |
| 2017 | $21.80 Billion | +20.29% |
| 2016 | $18.12 Billion | +18.64% |
| 2015 | $15.28 Billion | -- |
End of Day Market Cap According to Different Sources
On Mar 17th, 2026 the market cap of Edwards Lifesciences Corp was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $48.49 Billion USD |
| MoneyControl | $48.49 Billion USD |
| MarketWatch | $48.49 Billion USD |
| marketcap.company | $48.49 Billion USD |
| Reuters | $48.49 Billion USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.